Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QLQY | ISIN: US71716E1055 | Ticker-Symbol: PHG
Siehe auch PHARMING GROUP NV
München
06.06.25 | 08:17
10,300 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMING GROUP NV ADR Chart 1 Jahr
5-Tage-Chart
PHARMING GROUP NV ADR 5-Tage-Chart

Aktuelle News zur PHARMING GROUP NV ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.Pharming Group N.V.: Pharming Group to participate in June investor conferences263Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences...
► Artikel lesen
09.05.Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M3
08.05.Pharming Group N.V. - 6-K, Report of foreign issuer3
08.05.Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update447First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting...
► Artikel lesen
30.04.Pharming Group N.V.: Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director1
30.04.Pharming Group N.V. - 6-K, Report of foreign issuer5
PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln
25.04.Pharming Group N.V.: Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)6
24.04.H.C. Wainwright maintains Buy rating on Pharming Group stock15
24.04.NICE issues final guidance endorsing Pharming's APDS therapy3
24.04.Pharming Group N.V.: Pharming Group to report first quarter 2025 financial results on May 8330Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results...
► Artikel lesen
23.04.Pharming Group N.V. - 6-K, Report of foreign issuer1
23.04.Pharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDS362For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older...
► Artikel lesen
03.04.Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Q4/24 results/pipeline expansion - Buy337Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 03.04.2025 / 17:08 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
03.04.Pharming Group N.V. - 6-K, Report of foreign issuer2
03.04.Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers5
03.04.Pharming Group N.V.: Pharming Group announces the filing of its 2024 Annual Report and Form 20-F3
28.03.Pharming Group N.V.: Pharming Group to participate in April investor conferences304Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences...
► Artikel lesen
20.03.Pharming Group N.V. - 6-K, Report of foreign issuer2
20.03.Pharming Group N.V.: Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation426Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate...
► Artikel lesen
18.03.NICE recommends Pharming's Joenja as first treatment for ultra-rare immune disease APDS4
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1